RYAN'S QUEST

PO BOX 2544 

HAMILTON, NJ 08690

© 2019 Ryan's Quest       501(c) (3)Documentation

(609) 947-3611

June 18, 2015

 

Interim Clinical Data from Ongoing Phase 1b/2a Clinical Program Highlights Statistically Significant Improvements in Muscle Strength

 

Cambridge, Mass. - June 18 , 2015 - Akashi Therapeutics Inc., a clinical stage biopharmaceutical company developing treatments for Duchenne muscular dystrophy (DMD), today announced positive interim clinical data from an ongoing Phase 1b/2a clinical program with HT-100 (delayed-release halofugin...

Please reload

Please reload

Recent Posts
Search By Tags